Analysts expect that Galectin Therapeutics Inc (NASDAQ:GALT) will report earnings per share (EPS) of ($0.15) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Galectin Therapeutics’ earnings, with estimates ranging from ($0.18) to ($0.13). Galectin Therapeutics reported earnings per share of ($0.24) in the same quarter last year, which would suggest a positive year over year growth rate of 37.5%. The business is scheduled to announce its next quarterly earnings results on Tuesday, May 9th.
On average, analysts expect that Galectin Therapeutics will report full year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.72) to ($0.43). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.51) per share, with EPS estimates ranging from ($1.00) to ($0.18). Zacks’ earnings per share averages are an average based on a survey of analysts that follow Galectin Therapeutics.
Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Tuesday, March 28th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04.
GALT has been the topic of a number of research reports. FBR & Co restated a “market perform” rating and set a $2.00 price objective on shares of Galectin Therapeutics in a research report on Monday, April 3rd. HC Wainwright upgraded Galectin Therapeutics from a “neutral” rating to a “buy” rating and set a $3.50 price objective on the stock in a research report on Thursday, March 30th. Finally, Zacks Investment Research cut Galectin Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 16th.
Galectin Therapeutics (NASDAQ:GALT) traded down 1.51% during midday trading on Monday, reaching $3.27. The company’s stock had a trading volume of 437,398 shares. The firm’s market capitalization is $111.39 million. The firm has a 50 day moving average price of $2.10 and a 200 day moving average price of $1.30. Galectin Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.68.
A number of hedge funds have recently made changes to their positions in the stock. Advisor Group Inc. boosted its stake in shares of Galectin Therapeutics by 3.8% in the third quarter. Advisor Group Inc. now owns 413,125 shares of the company’s stock worth $467,000 after buying an additional 15,200 shares during the period. Courage Capital Management LLC bought a new stake in shares of Galectin Therapeutics during the third quarter worth $147,000. Finally, Benchmark Capital Advisors boosted its stake in shares of Galectin Therapeutics by 98.3% in the third quarter. Benchmark Capital Advisors now owns 118,200 shares of the company’s stock worth $134,000 after buying an additional 58,600 shares during the period. Hedge funds and other institutional investors own 10.01% of the company’s stock.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/0-15-eps-expected-for-galectin-therapeutics-inc-galt-this-quarter/1739293.html
Receive News & Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.